Overview

  • Product name
    Human Apolipoprotein AI ELISA Kit
    See all Apolipoprotein A I kits
  • Detection method
    Colorimetric
  • Precision
    Intra-assay
    Sample n Mean SD CV%
    Overall 5 2.1%
    Inter-assay
    Sample n Mean SD CV%
    Overall 3 2.9%
  • Sample type
    Cell culture supernatant, Serum, Heparin Plasma, EDTA Plasma, Citrate Plasma
  • Assay type
    Sandwich (quantitative)
  • Sensitivity
    59 pg/ml
  • Range
    0.313 ng/ml - 20 ng/ml
  • Recovery

    Sample specific recovery
    Sample type Average % Range
    Serum 115 111% - 122%
    Tissue Culture Media 89 85% - 92%
    Heparin Plasma 95 76% - 111%
    EDTA Plasma 112 108% - 115%
    Citrate Plasma 119 117% - 123%

  • Assay time
    1h 30m
  • Assay duration
    One step assay
  • Species reactivity
    Reacts with: Human
    Does not react with: Mouse, Rat, Rabbit, Goat, Chicken, Guinea pig, Hamster, Cow, Dog, Pig
  • Product overview

    Abcam’s Apolipoprotein AI (APOA1) in vitro SimpleStep ELISA® (Enzyme-Linked Immunosorbent Assay) kit is designed for the quantitative measurement of Apolipoprotein AI protein in human serum, plasma and cell culture supernatants.


    The SimpleStep ELISA® employs an affinity tag labeled capture antibody and a reporter conjugated detector antibody which immunocapture the sample analyte in solution. This entire complex (capture antibody/analyte/detector antibody) is in turn immobilized via immunoaffinity of an anti-tag antibody coating the well. To perform the assay, samples or standards are added to the wells, followed by the antibody mix. After incubation, the wells are washed to remove unbound material. TMB substrate is added and during incubation is catalyzed by HRP, generating blue coloration. This reaction is then stopped by addition of Stop Solution completing any color change from blue to yellow. Signal is generated proportionally to the amount of bound analyte and the intensity is measured at 450 nm. Optionally, instead of the endpoint reading, development of TMB can be recorded kinetically at 600 nm.

  • Notes

    Apolipoprotein AI (ApoA1) is secreted by the liver and small intestine and is a major protein of plasma HDL (high density lipoprotein). APOA-I participates in the reverse transport of cholesterol from tissues to the liver for excretion by promoting cholesterol efflux from tissues and by acting as a cofactor for the lecithin cholesterol acyltransferase (LCAT). Defects in APOA1I are associated with several diseases associated with low HDL levels (HDLD1 and HDLD2) and amyloidosis (AMYL8).

  • Tested applications
    Suitable for: Sandwich ELISAmore details
  • Platform
    Microplate

Properties

  • Storage instructions
    Store at +4°C. Please refer to protocols.
  • Components 1 x 96 tests
    10X APOA1 Capture Antibody 1 x 600µl
    10X APOA1 Detector Antibody 1 x 600µl
    10X Wash Buffer PT (ab206977) 1 x 20ml
    ab221825 - Antibody Diluent 5BI 1 x 6ml
    Human APOA1 Lyophilized Recombinant Protein 2 vials
    Plate Seals 1 unit
    Sample Diluent NS (ab193972) 1 x 50ml
    SimpleStep Pre-Coated 96-Well Microplate (ab206978) 1 unit
    Stop Solution 1 x 12ml
    TMB Substrate 1 x 12ml
  • Research areas
  • Function
    Participates in the reverse transport of cholesterol from tissues to the liver for excretion by promoting cholesterol efflux from tissues and by acting as a cofactor for the lecithin cholesterol acyltransferase (LCAT). As part of the SPAP complex, activates spermatozoa motility.
  • Tissue specificity
    Major protein of plasma HDL, also found in chylomicrons. Synthesized in the liver and small intestine. The oxidized form at Met-110 and Met-136 is increased in individuals with increased risk for coronary artery disease, such as in carrier of the eNOSa/b genotype and exposure to cigarette smoking. It is also present in increased levels in aortic lesions relative to native ApoA-I and increased levels are seen with increasing severity of disease.
  • Involvement in disease
    High density lipoprotein deficiency 2
    High density lipoprotein deficiency 1
    APOA1 mutations may be involved in the pathogenesis of amyloid polyneuropathy-nephropathy Iowa type, also known as amyloidosis van Allen type or familial amyloid polyneuropathy type III (PubMed:3142462 and PubMed:2123470). The clinical picture is dominated by neuropathy in the early stages of the disease and nephropathy late in the course. Death is due in most cases to renal amyloidosis.
    Amyloidosis 8
  • Sequence similarities
    Belongs to the apolipoprotein A1/A4/E family.
  • Post-translational
    modifications
    Palmitoylated.
    Met-110 and Met-136 are oxidized to methionine sulfoxides.
    Phosphorylation sites are present in the extracellular medium.
  • Cellular localization
    Secreted.
  • Information by UniProt
  • Alternative names
    • Apo-AI
    • ApoA-I
    • APOA1
    • APOA1_HUMAN
    • Apolipoprotein A-I
    • Apolipoprotein A-I(1-242)
    • Apolipoprotein A1
    • Truncated apolipoprotein A-I
    see all
  • Database links

Applications

Our Abpromise guarantee covers the use of ab189576 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Sandwich ELISA Use at an assay dependent concentration.

Images

  • Background-subtracted data values (mean +/- SD) are graphed.

  • Human serum and plasma (citrate) diluted 2.5x105 –fold to 8x106 –fold in Sample Diluent NS. Background subtracted data from duplicate measurements are plotted.

  • Interpolated concentrations of Apolipoprotein A1 in Human serum and plasma heparin. The concentrations of Apolipoprotein A1 were measured in duplicate and interpolated from the Apolipoprotein A1 standard curve and corrected for sample dilution. The interpolated dilution factor corrected values are plotted (mean +/- SD, n=2). The mean Apolipoprotein A1 concentration was determined to be 2500 µg/mL in serum and 1053ug/mL in plasma heparin.

  • Interpolated concentrations of Apolipoprotein A1 in Human serum from 10 donors. Serum from 10 apparently healthy male donors was measured in duplicate. The mean Apolipoprotein A1 concentration was determined to be 526 µg/mL with a range of 9.8-2011 µg/mL.

Protocols

References

This product has been referenced in:
  • Gugliucci A  et al. Short-term isocaloric fructose restriction lowers apoC-III levels and yields less atherogenic lipoprotein profiles in children with obesity and metabolic syndrome. Atherosclerosis N/A:N/A (2016). Sandwich ELISA ; Human . Read more (PubMed: 27451002) »
  • Tavori H  et al. Macrophage apoAI protects against dyslipidemia-induced dermatitis and atherosclerosis without affecting HDL. J Lipid Res N/A:N/A (2015). ELISA ; Human . Read more (PubMed: 25593328) »

See all 2 Publications for this product

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab189576.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up